These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26768480)

  • 1. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.
    Mango R; Vecchione L; Raso B; Borgiani P; Brunetti E; Mehta JL; Lauro R; Romeo F; Novelli G
    Expert Opin Pharmacother; 2005 Dec; 6(15):2565-76. PubMed ID: 16316297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular pharmacogenomics].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Apr; 171(17):1405-7. PubMed ID: 19413939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of cardiovascular drugs.
    Saleh A; Al-Abcha A; Pereira N
    Curr Opin Cardiol; 2023 May; 38(3):207-214. PubMed ID: 37016993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in the use of zebrafish for novel cardiac drug discovery.
    Keßler M; Rottbauer W; Just S
    Expert Opin Drug Discov; 2015; 10(11):1231-41. PubMed ID: 26294375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging human genetics to guide drug target discovery.
    Stitziel NO; Kathiresan S
    Trends Cardiovasc Med; 2017 Jul; 27(5):352-359. PubMed ID: 27686272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics in Cardiovascular Medicine.
    Weeke PE
    Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics: the genetics of variable drug responses.
    Roden DM; Wilke RA; Kroemer HK; Stein CM
    Circulation; 2011 Apr; 123(15):1661-70. PubMed ID: 21502584
    [No Abstract]   [Full Text] [Related]  

  • 12. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
    de Denus S; Dubé MP; Tardif JC
    Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
    Povsic TJ; Scott R; Mahaffey KW; Blaustein R; Edelberg JM; Lefkowitz MP; Solomon SD; Fox JC; Healy KE; Khakoo AY; Losordo DW; Malik FI; Monia BP; Montgomery RL; Riesmeyer J; Schwartz GG; Zelenkofske SL; Wu JC; Wasserman SM; Roe MT
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):445-458. PubMed ID: 28735360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular pharmacogenetics.
    Myburgh R; Hochfeld WE; Dodgen TM; Ker J; Pepper MS
    Pharmacol Ther; 2012 Mar; 133(3):280-90. PubMed ID: 22123178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Interface of Therapeutics and Genomics in Cardiovascular Medicine.
    Magavern EF; Kaski JC; Turner RM; Janmohamed A; Borry P; Pirmohamed M
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):663-676. PubMed ID: 33528719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implementation of Cardiovascular Pharmacogenomics.
    Pereira NL; Stewart AK
    Mayo Clin Proc; 2015 Jun; 90(6):701-4. PubMed ID: 26046404
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular pharmacogenomics and individualized drug therapy.
    Pereira NL; Weinshilboum RM
    Nat Rev Cardiol; 2009 Oct; 6(10):632-8. PubMed ID: 19707183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular pharmacogenomics.
    Johnson JA; Cavallari LH
    Exp Physiol; 2005 May; 90(3):283-9. PubMed ID: 15778411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress.
    Cavallari LH; Weitzel K
    Future Cardiol; 2015 May; 11(3):281-6. PubMed ID: 26021633
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomics and drug response in cardiovascular disorders.
    Siest G; Jeannesson E; Berrahmoune H; Maumus S; Marteau JB; Mohr S; Visvikis S
    Pharmacogenomics; 2004 Oct; 5(7):779-802. PubMed ID: 15469403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.